JP2007533299A - 抗ｒｈｅｓｕｓ−ｄおよび抗ｈｌａ−ｄｒ抗体のフコース含量／ガラクトース含量の比とａｄｃｃ活性の間の関連 - Google Patents

抗ｒｈｅｓｕｓ−ｄおよび抗ｈｌａ−ｄｒ抗体のフコース含量／ガラクトース含量の比とａｄｃｃ活性の間の関連 Download PDF

Info

Publication number
JP2007533299A
JP2007533299A JP2006534807A JP2006534807A JP2007533299A JP 2007533299 A JP2007533299 A JP 2007533299A JP 2006534807 A JP2006534807 A JP 2006534807A JP 2006534807 A JP2006534807 A JP 2006534807A JP 2007533299 A JP2007533299 A JP 2007533299A
Authority
JP
Japan
Prior art keywords
antibody
cell
activity
fucose
galactose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006534807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007533299A5 (https=
Inventor
ビオロー、ニコラス
ドゥ・ロメ、クリストフ
ジョリュー、シルビー
ノニィ、アンマニュエル
ブレル、ドミニク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Publication of JP2007533299A publication Critical patent/JP2007533299A/ja
Publication of JP2007533299A5 publication Critical patent/JP2007533299A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2006534807A 2003-10-20 2004-10-20 抗ｒｈｅｓｕｓ−ｄおよび抗ｈｌａ−ｄｒ抗体のフコース含量／ガラクトース含量の比とａｄｃｃ活性の間の関連 Pending JP2007533299A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312229A FR2861080B1 (fr) 2003-10-20 2003-10-20 Anticorps presentant un taux de fucose et de galactose optimise
PCT/FR2004/002686 WO2005040221A1 (fr) 2003-10-20 2004-10-20 Correlation du ratio taux de fucose / taux de galactose d’anticorps anti rhesus d et anti hla-dr avec l’activite adcc

Publications (2)

Publication Number Publication Date
JP2007533299A true JP2007533299A (ja) 2007-11-22
JP2007533299A5 JP2007533299A5 (https=) 2011-02-17

Family

ID=34385294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534807A Pending JP2007533299A (ja) 2003-10-20 2004-10-20 抗ｒｈｅｓｕｓ−ｄおよび抗ｈｌａ−ｄｒ抗体のフコース含量／ガラクトース含量の比とａｄｃｃ活性の間の関連

Country Status (9)

Country Link
US (1) US20070015239A1 (https=)
EP (1) EP1675873A1 (https=)
JP (1) JP2007533299A (https=)
AU (1) AU2004283924B2 (https=)
BR (1) BRPI0415565A (https=)
CA (1) CA2542881A1 (https=)
FR (1) FR2861080B1 (https=)
IL (1) IL174896A0 (https=)
WO (1) WO2005040221A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012105699A1 (ja) * 2011-02-03 2012-08-09 株式会社イーベック 補体依存性生物活性の高い抗体の産生法
JP2012522524A (ja) * 2009-04-07 2012-09-27 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体
JP2014525395A (ja) * 2011-08-10 2014-09-29 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジー 高度ガラクトシル化抗体
JP2016508515A (ja) * 2013-02-13 2016-03-22 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 高ガラクトシル化抗ＴＮＦ−α抗体およびその使用
JP2016509019A (ja) * 2013-02-13 2016-03-24 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 高ガラクトシル化抗ｈｅｒ２抗体およびその使用
US12247076B2 (en) 2015-07-06 2025-03-11 Laboratoire Français Du Fractionnement Et Des Biotechnologies Use of modified Fc fragments in immunotherapy

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
SI2073842T1 (sl) * 2006-09-10 2015-05-29 Glycotope Gmbh Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles
AU2013203482B2 (en) * 2006-09-10 2015-08-27 Glycotope Gmbh Fully human high yield production system for improved antibodies and proteins
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
EP1920781B1 (en) * 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
US20080227669A1 (en) * 2007-03-12 2008-09-18 Halliburton Energy Services, Inc. Corrosion-inhibiting additives, treatment fluids, and associated methods
EP1995309A1 (en) * 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
WO2010036443A1 (en) * 2008-09-26 2010-04-01 Eureka Therapeutics, Inc. Cell lines and proteins with variant glycosylation pattern
WO2011051231A1 (en) 2009-10-26 2011-05-05 F. Hoffmann-La Roche Ag Method for the production of a glycosylated immunoglobulin
WO2011124635A1 (en) 2010-04-07 2011-10-13 Humalys Binding molecules against chikungunya virus and uses thereof
EP2374816B1 (en) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409989A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Method to improve glycosylation profile for antibody
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
ES2686313T3 (es) 2011-08-22 2018-10-17 Glycotope Gmbh Microorganismos que portan un antígeno tumoral
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN106687481B (zh) * 2014-09-10 2022-03-22 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体
FR3035879B1 (fr) * 2015-05-07 2025-02-28 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle modifiee
EP3410849B1 (en) 2016-02-05 2023-07-05 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
WO2019011918A1 (en) 2017-07-10 2019-01-17 International - Drug - Development - Biotech TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
CA3146023A1 (en) 2019-07-05 2021-01-14 Iomx Therapeutics Ag Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
EP4175668A1 (en) 2020-07-06 2023-05-10 iOmx Therapeutics AG Antibodies binding igv of igsf11 (vsig3) and uses thereof
EP4491230A1 (en) 2023-07-14 2025-01-15 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
CN120548326A (zh) 2022-12-23 2025-08-26 艾奥麦克斯治疗公司 靶向白细胞免疫球蛋白样受体亚家族b1（lilrb1）和lilrb2的交叉特异性抗原结合蛋白（abp）、其组合和用途
WO2026003224A2 (en) 2024-06-26 2026-01-02 Iomx Therapeutics Ag Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077181A2 (fr) * 2000-04-12 2001-10-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps monoclonaux anti-rhesus d

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316463A1 (en) * 1987-11-13 1989-05-24 Northwestern University Murine hybridoma lym-1 and diagnostic antibody produced thereby
SE9203479L (sv) * 1992-01-20 1993-07-21 Rso Corp Saett och anordning vid elektronisk identifiering
FR2776096B1 (fr) * 1998-03-12 2000-06-23 Commissariat Energie Atomique Procede et systeme de lecture d'un ensemble dynamique d'etiquettes portant des codes d'identification distincts
FR2805637B1 (fr) * 2000-02-25 2002-12-13 Commissariat Energie Atomique Procede de lecture d'etiquettes electroniques par identification simultanee de leur code
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20040145474A1 (en) * 2002-11-15 2004-07-29 Schmidtberg Rupert A. RF identification reader for communicating condition information associated with the reader
FR2859843B1 (fr) * 2003-09-16 2005-12-23 Commissariat Energie Atomique Dispositif adressable par radiofrequence, systeme comportant une pluralite de tels dispositifs agences dans l'espace et procede d'adressage par activation d'un mode transparent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077181A2 (fr) * 2000-04-12 2001-10-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps monoclonaux anti-rhesus d

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522524A (ja) * 2009-04-07 2012-09-27 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体
WO2012105699A1 (ja) * 2011-02-03 2012-08-09 株式会社イーベック 補体依存性生物活性の高い抗体の産生法
JP2014525395A (ja) * 2011-08-10 2014-09-29 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジー 高度ガラクトシル化抗体
JP2016508515A (ja) * 2013-02-13 2016-03-22 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 高ガラクトシル化抗ＴＮＦ−α抗体およびその使用
JP2016509019A (ja) * 2013-02-13 2016-03-24 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 高ガラクトシル化抗ｈｅｒ２抗体およびその使用
US10174110B2 (en) 2013-02-13 2019-01-08 Laboratoire Français Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-TNF-α antibodies and uses thereof
JP2020073550A (ja) * 2013-02-13 2020-05-14 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 高ガラクトシル化抗ＴＮＦ−α抗体およびその使用
JP2020125286A (ja) * 2013-02-13 2020-08-20 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 高ガラクトシル化抗ｈｅｒ２抗体およびその使用
US12247076B2 (en) 2015-07-06 2025-03-11 Laboratoire Français Du Fractionnement Et Des Biotechnologies Use of modified Fc fragments in immunotherapy

Also Published As

Publication number Publication date
EP1675873A1 (fr) 2006-07-05
CA2542881A1 (fr) 2005-05-06
WO2005040221A1 (fr) 2005-05-06
BRPI0415565A (pt) 2007-01-02
AU2004283924B2 (en) 2010-12-02
IL174896A0 (en) 2006-08-20
FR2861080A1 (fr) 2005-04-22
FR2861080B1 (fr) 2006-02-17
US20070015239A1 (en) 2007-01-18
AU2004283924A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
AU2004283924B2 (en) Correlation between the fucose content / galactose content ratio of anti-rhesus-D and anti-HLA-DR antibodies and the ADCC activity
Vattepu et al. Sialylation as an important regulator of antibody function
RU2466189C2 (ru) ВЕКТОР ДЛЯ ЭКСПРЕССИИ ПОЛИПЕПТИДОВ С СИАЛИДАЗНОЙ АКТИВНОСТЬЮ, СПОСОБ ОБЕСПЕЧЕНИЯ СИАЛИДАЗНОЙ АКТИВНОСТИ В КУЛЬТУРЕ КЛЕТОК И СПОСОБ РЕГУЛИРОВАНИЯ СВОЙСТВ Fc-СОДЕРЖАЩИХ МОЛЕКУЛ, ЭКСПРЕССИРУЕМЫХ В ЛИНИИ КЛЕТОК
AU2006265676B2 (en) Methods and compositions with enhanced therapeutic activity
Jefferis Isotype and glycoform selection for antibody therapeutics
Jefferis et al. Glycosylation of antibody molecules: structural and functional significance
van Berkel et al. N‐linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG
US11821017B2 (en) Methods to produce single glycoform antibodies
Jefferis Glyco-engineering of human IgG-Fc to modulate biologic activities
JP2022500371A (ja) 抗体依存性細胞介在性細胞傷害の調節方法
Nimmerjahn Role of Antibody Glycosylation in Health, Disease, and Therapy
Jefferis The antibody paradigm: present and future development as a scaffold for biopharmaceutical drugs
CN101466402A (zh) 糖基化改造的抗体治疗
Jeffries Post-translational modification of recombinant antibody proteins

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070905

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20091027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100928

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101213

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120327